dysfunction, ataxia and areflexia. In North America and Europe, around 5% of patients with GBS have the axonal subtypes, whereas in Central and South America, Japan and China axonal subtypes account for 30-47% of cases [5] ; Miller-Fisher syndrome has been found to account for around 5% of cases of GBS [3, 5] . Standard criteria for the diagnosis of GBS were published in 1978 by a National Institute of Neurological and Communicative Diseases (NINCDS) committee. The criteria include clinical features such as progression, relative symmetry and mild sensory symptoms or signs as well as levels of protein in cerebrospinal fluid, and electrodiagnostic features, such as nerve conduction slowing or blocking [2] . Typical treatment regimens for GBS include plasma exchange and intravenous immunoglobulin. Both treatments are thought to be equally efficacious, but Tsai et al. [6] showed that intravenous immunoglobulin may be cheaper due to patients having fewer complications and requiring a shorter stay in hospital; direct health care costs were estimated to be approximately USD 110,000 in the USA.
Insight into the incidence of disease is important for the identification of trends in relation to patient characteristics, such as age and geographical location, and to determine any changes in incidence following exposure to new environmental factors. Previous reviews evaluating the incidence of GBS have found rates to be between 0.16 and 4.0/100,000/year in individuals of all ages [3, 4] and between 0.5 and 1.5/100,000/year in those under 18 years [7] . The highest rates have been reported in adults, especially those aged over 75 years [4, 5] . Unusually for an autoimmune disease, higher incidence rates have been reported in males than females [4] .
To our knowledge, no systematic evaluation of published studies of the incidence of GBS has been published. Previous epidemiological reviews of GBS include: Sladky [7] who reported on incidence of GBS in children, Govoni and Granieri [3] who included studies published between 1978 and 2000 and described overall trends in incidence rates, and Hughes and Rees [4] who tabulated rates from 35 studies published between 1958 and 1996. The objectives of this literature review were to identify reliable estimates of GBS incidence, to compare rates by age and geography, and to examine any changes in incidence over time.
Method
Searches of the Medline (1980 Medline ( -2008 , EMBASE (1980 EMBASE ( -2008 and Science Direct (1980 Direct ( -2008 databases were carried out using the keywords 'Guillain-Barré Syndrome' or 'polyradiculoneuropathy' and 'incidence' or 'epidemiology'. The 2 disease terms were used because the MeSH term 'Guillain-Barré syndrome' was only used in Medline from 1998.
The inclusion criteria were that the studies reported original work, that a reasonable effort had been made by the authors to include all incident cases and that the estimates of population size and person-time contributed during the study period were accurate. When assessing the likelihood of missing incident cases, papers were evaluated as follows: (1) for case-finding studies, did the authors ensure that all of the subjects contributing person-time to the denominator data were available as potential cases and did the authors check all relevant medical records? (2) for all studies, were cases checked to ensure that they were incident and not prevalent? (3) for all studies, did the authors ensure that the cause of GBS was autoimmune and it was not secondary to another disease?
The titles and abstracts (where available) of all of the studies identified by the searches were reviewed by 2 investigators. Studies published in English, French, German, Spanish or Dutch were included. The full text of all potentially relevant papers was appraised and decisions about inclusion of papers were discussed by all authors. Review papers were searched for secondary references reporting on original research; secondary references found from any of the other papers reviewed were also included.
A standard data abstraction form was used to record all details of the papers reviewed (appendix 1). Each study was classified as being at low, medium or high risk of under-or overestimation of reported incidence rates by considering the reliability of numerator and denominator data. For instance, inclusion of prevalent cases or those thought not to be caused by autoimmunity will have led to overestimated rates, as will underestimated denominator data. Conversely, missing cases or an overestimated denominator (e.g. a catchment area from which not all inhabitants had access to hospital services) would be considered to result in underestimated incidence rates. Explanations provided by the papers' authors as to why incidence rates were as expected or whether they were considered to be an over-or underestimate of the true incidence rate were taken into account in this process. If the extent of likely error was considered to be very great, the study was excluded. To minimise subjectivity, this assessment was agreed between the authors and random checks were performed to ensure consistency. Rates are presented as the number of cases/100,000/year and where sufficient data were given in the paper, rates were checked for accuracy. Figure 1 shows the results of the database searches and subsequent filtering of search results. A list of all of the references considered for this study but excluded is available on request from the authors.
Results
Of the 457 papers rejected at the abstract review stage, nearly half did not focus on GBS as the subject of the paper and one fifth did not investigate incidence of GBS; other key reasons for rejecting papers at this stage included those reviewing the disease, case series, those investigating outcomes of vaccinations and those reporting on incidence of a disease other than GBS. Following review of the full papers, 31 papers were rejected; key reasons for this included papers that reviewed the disease and did not provide primary data on incidence, papers reporting data given in other papers already included, incidence rates not presented and too few data given to calculate incidence rates and papers reporting incidence data thought to be very unreliable. Each of the 63 studies included in this review is described in table 1 , first for children and then for adults grouped by continent. Incidence rates broken down by age band are given in table 2 .
Incidence Rates
The incidence rates found for GBS varied between 0.38/100,000/year (95% CI 0.25-0.56) in Finland [8] and 2.53/100,000/year (95% CI 1.87-3.35) in Curaçao [9] ( table 1 ).
Geographical Variation
Most of the studies included in this review were from Europe and North America where the majority of incidence rates were between 0.84/100,000/year (Finland) [10] and 1.91/100,000/year (Italy) [11] . For other parts of the world, very few studies were found, and therefore it is difficult to comment on any geographical trends. For the data presented, a comparison of these rates with those of Europe and North America suggest that incidence was lower in China [12, 13] , Hong Kong [14] and Brazil [15] , similar in Tanzania [21] , Australia [16, 17] and Japan [18] and slightly higher in the Middle East [19, 20] and Curaçao [9] .
Variation over Time
Most studies covered time periods between 1980 and 2000 [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Between 1980 and 2000, the incidence was between 1.0/100,000/year and 1.8/100,000/ year. Only 3 studies reported rates from 2000 onwards, and these were thought to be unreliable [20, 44, 45] .
Variation with Age
In the majority of studies that included incidence rates broken down by age, increases in rates were observed in most studies of people aged 50 years or more [11, 17, 22, 26, 31-33, 35-39, 46-49] , with some showing a decrease in the highest age group of 6 80 years [22, 26, 31, [35] [36] [37] [38] [47] [48] [49] .
Overall incidence rates in children ranged from 0.34/100,000/year to 1.34/100,000/year [31, 34] . In the studies that investigated incidence in children (0-9 years) and teenagers (10-19 years) , most showed an increase in incidence with increasing age [19, 37, 38, [48] [49] [50] [51] , although some demonstrated decreases [12, 13, 17, 46, 47] . Figures in parentheses are 95% CI. RUE = Risk of underestimation; ROE = risk of overestimation; * = low; ** = medium; *** = high; MF = Miller-Fisher; URI = upper respiratory tract infection; GI = gastrointestinal infection. 1 Rate checked and confirmed. 2 CI added. 3 Standardised rate. 4 Date used in incidence calculations is date of diagnosis. 5 Rate calculated from number of cases and population data provided in the paper. 6 Date used in incidence calculations is date of first admission to hospital. 
Clinical Variants of GBS
Very few studies included in this review gave information about incidence of the clinical variants of GBS -of those studies that did, the main variant of GBS, MillerFisher syndrome, was much less common than GBS. If cases of these diseases were included in any studies of GBS incidence, then the overall incidence rate would only be overestimated by a small amount.
Antecedent Infection
A number of the studies included in this review gave details of numbers of cases reporting an antecedent infection, usually less than 4 weeks, before onset of GBS. These data have been recorded in table 1 along with a breakdown of the type of infection, where given. In most studies reporting this information, 40-70% of cases recorded an infection before onset with 22-53% having an upper respiratory tract infection and 6-26% a gastrointestinal infection. Children's rates were higher, with 67-85% of all cases reporting an infection: 50-70% were respiratory infections and 7-14% gastrointestinal infections.
Seasonal Variation
The issue of seasonal variation in incidence was raised in some studies although none reported significant differences in levels of onset of GBS between seasons [16, 28, 29, 50, [52] [53] [54] . Some found more cases in colder months [9, 19, 20, 46, 55, 56] although a cluster of cases was reported in spring and summer in Brazil [15] , during the winter and June in the Netherlands [33] and during autumn in Sweden [37] .
Study Method
Study design is an important consideration when comparing incidence rates between different studies. In this review, the studies included were of 3 types: prospective [11-13, 20, 24, 27, 29-32, 36, 38, 47, 53, 54, 57-59] , retrospective medical record review [9, 14-19, 21, 25, 26, 33-35, 41, 46, 50-52, 55, 56, 60-66] and retrospective database studies with [8, 10, 40, 67, 68] or without [22, 23, 37, 39, 42-45, 48, 49 ] the review of cases by a clinician. At first glance, it would appear that study design did not have a sizeable effect as the incidence rates found were similar. However, when incidence rates were compared by type of study, some trends became apparent. For the prospective studies, the majority of incidence rates were between 1.11/100,000/year and 1.66/100,000/year; for the retrospective record review studies and the database studies with record review, most were between 0.83/ 100,000/year and 1.77/100,000/year and for the database studies where a review of cases was not performed, 1.14/ 100,000/year to 2.2/100,000/year. Prospective studies are usually the most reliable; using this as the standard suggests that some of the database studies overestimated incidence rate and some of the retrospective record review studies underestimated rates.
Most patients diagnosed with GBS will be hospitalised due to the nature of the disease [8, 26, 32, 33, [35] [36] [37] 64 ] : 3 studies reported small numbers of outpatient or community patients identified in their studies compared with numbers of hospitalised GBS cases [12, 32, 38] . Ten studies noted the inclusion of mild cases in their studies [16, 24, 29, 33, 38, 45, 46, 50, 57, 59 ] and the design of other studies implied the inclusion of mild cases: 2 studies using general practitioner records [22, 23] , a surveillance study [54] , a door-to-door survey [58] and the record linkage system used by the Mayo Clinic [66] . Of those studies that used mainly hospital records, 2 noted that all patients were given intravenous immunoglobulin or plasma exchange therapy [20, 67] , and this implies that only serious cases were included, whereas others reported proportions of patients receiving these therapies of between 24 and 49% for intravenous immunoglobulin and 34-51% receiving plasma exchange [26, 27, 30, 47, 61] . Ten studies reported missing mild cases [12, 32, 36, 64, 69, 70] or reported finding it difficult to detect mild cases if they had not been admitted to hospital [17, 25, 37, 62] .
Discussion
Most of the incidence rates of GBS reported were between 1.1/100,000/year and 1.8/100,000/year with lower rates reported in children ( ! 16 years) of 0.4/100,000/year to 1.4/100,000/year. Most of the studies included were from Europe and North America where the rates found were similar.
A number of studies have commented on a bimodal pattern of incidence by age, with peaks occurring in young adults and the elderly [3, 24, 71] . In this review, only 1 study [19] (out of 24) found a peak in incidence in young adults, although the rates were not adjusted and a high proportion of young adults in this area could have biased the incidence rates found.
The majority of studies used the recognised NINCDS criteria or a comparable set of diagnostic criteria, and this allowed comparisons to be made between studies. One important difference between studies that should be highlighted is the study method used. In this review, the overall incidence rates found by the prospective studies Incidence of GBS by age band (only those studies that gave incidence by age band are included in the table) Winner and Evans Cheng et al. [12] Data are presented as incidence rates per 100,000 people/year, with 95% CI in parentheses. 1 Standardised rate. 2 Rate read from graph. 3 Rate calculated from number of cases and population data provided in the paper. 4 Date used in incidence calculations is date of first admission to hospital. 5 CI added. 6 Rate checked and confirmed.
and the database studies that did not review cases were higher than those found by the retrospective studies that reviewed medical records. Prospective studies of incidence are thought to be the most accurate provided the ascertainment of cases and determination of denominator are reliable. This is thought to be true of the prospective studies included in this review, so the incidence rates from these are likely to be the best approximation available for the true incidence of GBS. The range of incidence rates found by the retrospective studies where medical records were reviewed produced slightly lower incidence rates, which indicates that some cases may have been missed by these studies. Conversely, it is possible that the studies using databases where medical records were not reviewed overestimated the incidence rates. Bogliun et al. [72] compared case ascertainment between a hospital discharge database and a registry, and found that over half of the 'cases' identified in the discharge database had either not had their diagnosis confirmed or had been double-counted through re-admission to hospital. The possibility of inaccurate coding could also contribute to overestimation of cases in this type of study. The database studies did not provide any indication of the criteria used when the original diagnosis was made, which is more likely to be a feature of this particular study method than a lack of regard for set diagnostic guidelines. The identity of GBS as a single homogenous clinical entity is evolving and reference to GBS as a term covering the disease subtypes AIDP, AMAN, AMSAN and MillerFisher syndrome is becoming more common [71, 73] . GBS also has links with chronic diseases, including chronic inflammatory demyelinating neuropathy and subacute demyelinating polyneuropathy [71] . Possible implications for interpretation of incidence rates in epidemiological studies of GBS are that most of the studies included in this review used the NINCDS criteria, which do not include the symptoms of Miller-Fisher syndrome but do include AIDP, AMAN and AMSAN. Therefore, if Miller-Fisher syndrome is to be included in the definition, then some of the rates reported here derived from studies using NINCDS criteria will be slight underestimates of the true incidence. Geographical patterns of incidence of AIDP, AMAN and AMSAN have been reported [5, 73] . Very few studies in this review included information on the incidence of variants of GBS, and those that did concentrated on whether cases of Miller-Fisher syndrome were included; it was not possible to determine whether there was a geographical difference between incidence of AIDP, AMAN and AMSAN. A link between the incidence of clinical variants and preceding infection was made by Govoni et al. [29] who compared GBS incidence with clinical variants of GBS including MillerFisher syndrome, polyneuritis cranialis, sensory form, acute pandysautonomia and chronic inflammatory demyelinating polyneuropathy. They found that a higher number of cases with preceding infection amongst individuals with clinical variants than amongst those with GBS (88% compared with 54% in their study), and that the disease was milder at nadir for clinical variants of GBS. Some investigators recommend that the NINCDS criteria are widened to include clinical variants and this might result in more cases being identified [29, 66] .
The association with antecedent viral and upper respiratory infections before onset of GBS has been known for over 100 years, although the suggested link between Campylobacter jejuni and GBS is much more recent [73] . Potential links have been reported between Campylobacter jejuni and axonal forms of GBS [73] . It is acknowledged that the reporting of antecedent infections is likely to be more accurate in prospective than in retrospective studies; for example less than 40% of cases of GBS were reported to be preceded by an infection in 3 retrospective studies in Italy [28, 31, 55] whereas a prospective study from Italy reported a rate of preceding infection of 70% [27, 47] . It is therefore reasonable to assume that most cases of GBS are triggered by antecedent infection, although no indications were given as to the likely cause of the majority of the remaining cases. Hughes and Rees [4] noted that the lack of obvious seasonal changes in incidence may be because the infections found most frequently to trigger this disease, respiratory and enteric infections, have opposite seasonality of occurrence. Two studies investigated potential seasonal variations in cases for those who reported an antecedent infection before onset of GBS: Larson et al. [56] found seasonal variation to be more pronounced in this group, but Paolino et al. [28] did not find a significant association with onset in cold or warm months.
Conclusions
Overall the best estimate of the incidence of GBS is between 1.1/100,000/year and 1.8/100,000/year with lower rates reported in children ( ! 16 years) of around 0.6/100,000/year. The review reported mostly on studies from Europe and North America. Few rates were presented from other parts of the world, particularly Asia and Africa, and this makes it difficult to comment on possible geographical variations. Incidence increased with age from 50 years; we were unable to confirm the suggestion that bimodality exists in the incidence of GBS. Antecedent infections, mainly upper respiratory and gastrointestinal infections, preceded up to 70% of cases reported.
The widespread use of the NINCDS criteria provides consistency across studies. Differences in incidence rates between studies with different methods were found: prospective studies were thought to be the most reliable; however, large differences in incidence rates between the various types of studies were not found.
